Jagsonpal Pharmaceuticals shareholding pattern

JAGSNPHARM

169

0.35 (0.21%)
Last updated on 27 Feb, 2026 | 15:29 IST
Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Jagsonpal Pharmaceuticals Shareholding Pattern

  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

67.39%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

2.12%

Domestic Institutional Investors

0.15%

Retail

30.34%

Others

0%

Total Promoters
MAR '25
67.78%
JUN '25
67.65%
SEP '25
67.54%
DEC '25
67.39%

Summary

For Year 2025-26, Jagsonpal Pharmaceuticals reports the following shareholding: Total Promoters at 67.39%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 2.12%, Domestic Institutional Investors at 0.15%, and Retail at 30.34%. This breakdown provides a quick snapshot of ownership distribution for Jagsonpal Pharmaceuticals in 2025-26.

Jagsonpal Pharmaceuticals FAQs

As of 03-2026, the promoter shareholding in Jagsonpal Pharmaceuticals stands at 67.39% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Jagsonpal Pharmaceuticals is 2.12% and 0.15% respectively.

The retail shareholding of the Jagsonpal Pharmaceuticals is 30.34%.

Changes in shareholding patterns of Jagsonpal Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Jagsonpal Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost